AbbVie to Present Phase 3 Etentamig Results and Data from Broad Multiple Myeloma Portfolio at the 2026 International Myeloma Society (IMS) Meeting
Rhea-AI Summary
AbbVie (ABBV) will present full Phase 3 CERVINO results for investigational BCMA x CD3 T-cell engager etentamig at the 2026 International Myeloma Society (IMS) meeting in Glasgow, where the drug met dual primary endpoints of objective response rate (ORR) and progression-free survival (PFS) versus standard available therapies in adults with triple-class exposed relapsed/refractory multiple myeloma (RRMM).
The company will also share multiple presentations spanning real-world outcomes, treatment patterns, infection-related healthcare utilization and costs, and combination strategies. Additional data will cover investigational assets ABBV-2001 (ISB 2001), a CD38 x BCMA x CD3 trispecific T-cell engager, and surzetoclax, a BCL-2 inhibitor, including monotherapy and combination studies across different myeloma settings. All three agents remain investigational and are not approved by health authorities.
Positive
- Etentamig Phase 3 CERVINO trial met dual primary endpoints of ORR and PFS versus standard available therapies in triple-class exposed RRMM
- Multiple myeloma portfolio breadth highlighted via presentations on ABBV-2001, surzetoclax, combinations, real-world outcomes and treatment patterns across several IMS 2026 sessions
Negative
- Etentamig, ABBV-2001 and surzetoclax are investigational only and not approved by any health authorities; safety and efficacy remain under evaluation
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Plenary presentation will feature Phase 3 CERVINO results demonstrating that etentamig met the study's dual primary endpoints of objective response rate (ORR) and progression-free survival (PFS) in relapsed/refractory multiple myeloma (RRMM)
- Additional presentations highlight research across the breadth of AbbVie's multiple myeloma portfolio, including ABBV-2001 (ISB 2001), a trispecific T-cell engager and surzetoclax, a BCL-2 inhibitor, and combination approaches
- AbbVie's IMS presence reinforces its strategy to build a differentiated multiple myeloma portfolio across complementary mechanisms designed to address disease complexity and evolving patient needs
Beyond the full CERVINO data, AbbVie will present research demonstrating the breadth of its myeloma pipeline across T-cell engagers, targeted therapies, rational combinations and real-world evidence. Presentations will feature investigational assets including ABBV-2001 (ISB 2001), a CD38 x BCMA x CD3 trispecific T-cell engager, and surzetoclax, a BCL-2 small-molecule inhibitor, alongside studies evaluating etentamig across multiple treatment settings.
Additional presentations from these investigational assets will explore treatment sequencing, infection-related healthcare utilization and costs, and real-world outcomes, reinforcing AbbVie's strategy to advance understanding of disease heterogeneity, mechanisms of resistance and the evolving needs of patients living with multiple myeloma.
"Despite meaningful progress in multiple myeloma, the disease remains incurable and patients continue to face challenges related to treatment resistance, disease heterogeneity, tolerability and durable disease control," said Daejin Abidoye, M.D., vice president and therapeutic area head, oncology, solid tumor and hematology at AbbVie. "Our presence at IMS reflects the depth and momentum of our multiple myeloma strategy as we advance our scientifically differentiated portfolio, spanning T-cell engagers, targeted therapies and rational combinations designed to address distinct disease mechanisms and evolving patient needs, with the goal of delivering more precise, durable and accessible treatment options."
The full list of AbbVie presentations at IMS includes:
Note: All presentation times are listed in local
|
Abstract Title |
Date/Time |
Session |
Abstract Number |
|
Real-World (RW) Patterns, and Outcomes (TCE) (RRMM) in Data Platform
|
Wednesday,
12:00–1:00 PM |
Poster Presentation
|
PA-386 |
|
Etentamig in Patients with Multiple Myeloma (RRMM)
|
Thursday, September
12:00–1:00 PM |
Poster Presentation
|
PA-181 |
|
A Phase 1/2, Open-Label, Evaluate the Safety and Monotherapy or
|
Friday, September 25,
12:00–1:00 PM |
Poster Presentation
|
PA-008 |
|
Phase 1/2, Open-Label, Selected Patients with Multiple Myeloma (RRMM)
|
Friday, September 25,
12:00–1:00 PM |
Poster Presentation |
PA-346 |
|
Real-World (RW) T-cell Redirecting
|
Friday, September 25,
12:00–1:00 PM |
Poster Presentation
|
PA-387 |
|
CERVINO: Phase (Ph) 3 Investigator's Choice of Therapies (SAT) in Exposed Relapsed or (RRMM)
|
Friday, September 25,
3:00–5:00 PM |
Plenary Session
Hall 5 |
LBA-01 |
|
Etentamig Combined With Dexamethasone Refractory Multiple Prior Lines of Therapy: A
|
Saturday, September
8:30–9:30 AM
|
Oral Presentation
Abstract Session 9
Hall 5 |
OA-24 |
|
AbbVie Advances ABBV-
|
Saturday, September
9:30–10:20 AM |
Oral Presentation
Future Targets and
Hall 5
|
N/A |
|
Surzetoclax: A Potentially Inhibitor for the Treatment with t(11;14) Translocation Expression
|
N/A |
Poster Presentation
|
PA-468 |
More information about the IMS 2026 meeting, including AbbVie's presence, will be available here.
Additional information around AbbVie's ongoing clinical trials in multiple myeloma can be found at clinicaltrials.gov.
Etentamig, ABBV-2001 (ISB 2001) and surzetoclax are investigational medicines and are not approved by any health authorities worldwide. The safety and efficacy of these investigational medicines are under evaluation as part of ongoing clinical studies.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.
About AbbVie in Oncology
AbbVie is committed to elevating standards of care and bringing transformative therapies to patients worldwide living with difficult-to-treat cancers. We are advancing a dynamic pipeline of investigational therapies across a range of cancer types in both blood cancers and solid tumors. We are focusing on creating targeted medicines that either impede the reproduction of cancer cells or enable their elimination. We achieve this through various targeted treatment modalities and biology interventions, including small molecule therapeutics, antibody-drug conjugates (ADCs), immuno-oncology-based therapeutics, multispecific antibodies and novel CAR-T platforms. Our dedicated and experienced team joins forces with innovative partners to accelerate the delivery of potential breakthrough medicines.
Today, our expansive oncology portfolio comprises approved and investigational treatments for a wide range of blood cancers and solid tumors. We are evaluating more than 35 investigational medicines in multiple clinical trials across some of the world's most widespread and debilitating cancers. As we work to have a remarkable impact on people's lives, we are committed to exploring solutions to help patients obtain access to our cancer medicines. For more information, please visit http://www.abbvie.com/oncology.
Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2025 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
|
Media: Sourojit (Jit) Bhowmick, Ph.D. |
Investors: Liz Shea |
View original content:SOURCE AbbVie
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When and where will AbbVie present its multiple myeloma data?
AbbVie will present new multiple myeloma data at the 23rd International Myeloma Society (IMS) Annual Meeting, taking place September 23–26, 2026, in Glasgow, Scotland. The CERVINO Phase 3 etentamig plenary presentation is scheduled for Friday, September 25, 2026, from 3:00–5:00 PM in Plenary Session Hall 5.
What key etentamig studies beyond CERVINO will be featured at IMS 2026?
Other etentamig-focused presentations include a poster on RRMM patients previously exposed to BCMA-targeted therapy; a Phase 1/2 open-label platform study of etentamig as monotherapy or in combinations in multiple myeloma; and a Phase 1/2 platform study of surzetoclax with etentamig in biomarker-selected RRMM. There will also be an oral presentation on etentamig combined with pomalidomide plus dexamethasone after 1–3 prior lines of therapy.
Which other investigational AbbVie agents in multiple myeloma will have dedicated IMS presentations?
ABBV-2001 (ISB 2001), a CD38 x BCMA x CD3 trispecific T-cell engager, will be discussed in an oral presentation on its single-molecule trispecific T-cell engager approach. Surzetoclax, a BCL-2 inhibitor, will be featured in a poster describing it as a potential treatment for multiple myeloma with t(11;14) translocation or high BCL-2 expression, and in combination studies with etentamig.
What real-world or health economics data will AbbVie present at IMS 2026?
Planned presentations include real-world characteristics, treatment patterns and outcomes in triple-class exposed RRMM in Europe using the HARMONY Big Data Platform, as well as real-world infection-related healthcare resource utilization and costs in multiple myeloma patients receiving T-cell redirecting therapies.